Nektar Therapeutics is getting $50 million up front in a $175 million licensing deal with Bayer Healthcare for the successful development of a new therapy for severe pneumonia. Nektar will deploy its pulmonary technology to deliver aminoglycoside antibiotic NKTR-061. The pact includes a rich co-promotion deal for the U.S. market along with a royalty split on sales outside the U.S.
- see this release
- read the AFX report on the deal
Related Articles:
Nektar settles university patent fight. Report
Nektar gains fast track for lung infection drug. Report